Rhea-AI Impact
Rhea-AI Sentiment
(Very Positive)

Kazia Therapeutics reported successful completion of stage 1 of the EVT801 Phase 1 clinical trial in advanced cancer patients. The Safety Review Team confirmed meeting primary and secondary objectives, determining a recommended phase 2 dose at 400mg BID. EVT801 showed promising clinical activity, especially in patients with advanced ovarian cancer. The trial included 26 patients across six dosing cohorts, with EVT801 being well-tolerated. CEO Dr. John Friend emphasized the need for new therapies in high-grade serous ovarian cancer patients.

Kazia Therapeutics ha riportato il completamento con successo della fase 1 del trial clinico di fase 1 EVT801 in pazienti con cancro avanzato. Il Team di Revisione della Sicurezza ha confermato il raggiungimento degli obiettivi primari e secondari, stabilendo una dose raccomandata per la fase 2 di 400mg BID. EVT801 ha mostrato un'attività clinica promettente, in particolare nei pazienti con cancro ovarico avanzato. Il trial ha incluso 26 pazienti suddivisi in sei coorti di dosaggio, con EVT801 ben tollerato. Il CEO Dr. John Friend ha sottolineato la necessità di nuove terapie per i pazienti con cancro ovarico sieroso di alto grado.
Kazia Therapeutics informó sobre la finalización exitosa de la fase 1 del ensayo clínico de EVT801 en pacientes con cáncer avanzado. El Equipo de Revisión de Seguridad confirmó que se cumplieron los objetivos primarios y secundarios, determinando una dosis recomendada para la fase 2 de 400mg BID. EVT801 mostró una actividad clínica prometedora, especialmente en pacientes con cáncer de ovario avanzado. El ensayo incluyó a 26 pacientes distribuidos en seis cohortes de dosificación, y EVT801 fue bien tolerado. El CEO Dr. John Friend destacó la necesidad de nuevas terapias para pacientes con cáncer de ovario seroso de alto grado.
Kazia 치료제가 EVT801 1단계 임상 시험의 1단계 완료를 성공적으로 보고했습니다. 안전 검토 팀은 1차 및 2차 목표 달성을 확인하고 400mg BID의 2단계 추천 용량을 결정했습니다. EVT801은 특히 진행성 난소암 환자에서 긍정적인 임상 활동을 보였습니다. 이 임상 시험에는 6개 용량 코호트에 걸쳐 26명의 환자가 포함되었으며, EVT801은 잘 견디었습니다. CEO John Friend 박사는 고등급 장액성 난소암 환자를 위한 새로운 치료법의 필요성을 강조했습니다.
Kazia Therapeutics a annoncé l'achèvement réussi de la phase 1 de l'essai clinique de phase 1 EVT801 chez des patients atteints de cancer avancé. L'équipe de révision de la sécurité a confirmé la réalisation des objectifs primaires et secondaires, déterminant une dose recommandée pour la phase 2 de 400mg BID. EVT801 a montré une activité clinique prometteuse, notamment chez les patients atteints de cancer ovarien avancé. L'essai comprenait 26 patients répartis en six cohortes de dosage, EVT801 étant bien toléré. Le PDG Dr. John Friend a souligné le besoin de nouvelles thérapies pour les patients atteints de cancer ovarien séreux de haut grade.
Kazia Therapeutics berichtete über den erfolgreichen Abschluss der Phase 1 der klinischen Prüfung der EVT801 in Patienten mit fortgeschrittenem Krebs. Das Sicherheitsüberprüfungsteam bestätigte die Erreichung der primären und sekundären Ziele und bestimmte eine empfohlene Dosis für Phase 2 von 400mg BID. EVT801 zeigte vielversprechende klinische Aktivität, insbesondere bei Patienten mit fortgeschrittenem Eierstockkrebs. Die Studie umfasste 26 Patienten in sechs Dosiskohorten, wobei EVT801 gut vertragen wurde. CEO Dr. John Friend betonte die Notwendigkeit neuer Therapien bei Patienten mit hochgradigem serösem Eierstockkrebs.
  • Successful completion of stage 1 of EVT801 Phase 1 clinical trial

  • Primary and secondary objectives met, establishing a recommended phase 2 dose

  • Promising clinical activity observed, particularly in advanced ovarian cancer patients

  • EVT801 well-tolerated across different dosing cohorts

  • CEO highlights the significant unmet need for new therapies in high-grade serous ovarian cancer

  • None.

The recent announcement concerning the EVT801 Phase 1 clinical trial denotes a significant juncture for Kazia Therapeutics, as it advances through the clinical development stages. From a medical research perspective, the identification of the recommended phase 2 dose provides a tangible progression point, suggesting a favorable safety profile and pharmacokinetics conducive to further study. With 46% of ovarian cancer patients showing stable disease or better, there appears to be a therapeutic potential, particularly in a context where limited treatment options are available. This merits further attention as the drug progresses, given the high unmet needs in high-grade serous ovarian cancer.

As an expert in oncology clinical trials, the completion of a Phase 1 study with a novel VEGFR3 tyrosine kinase inhibitor like EVT801 presents a noteworthy step, especially in a complex and urgent field such as advanced ovarian cancer. The reported stability in disease across multiple patients suggests preliminary efficacy, though these findings are prelude to the more rigorous Phase 2 and 3 trials that will elucidate the true clinical benefits and risks. A multi-cohort Phase 1 trial that encompasses a variety of cancer types also underlines the potential for broad applications of EVT801, which could be pivotal for its future commercial positioning.

Kazia Therapeutics' successful Phase 1 trial outcome is likely to resonate positively with investors and the broader market. The development of EVT801 may attract potential partnership opportunities, bolstering Kazia's portfolio and market value. However, investors should remain aware of the inherent risks in drug development, particularly as the drug enters the more capital-intensive Phase 2 trials. Long-term potential hinges on navigating regulatory pathways, securing further funding and eventual market acceptance, alongside the competitive landscape of oncology treatments, where numerous companies vie for a share of the market.

SYDNEY, May 1, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce that the Safety Review Team (SRT) of the EVT801 Phase 1 clinical trial has concluded that the primary and secondary objectives of stage 1 of the trial have successfully been met.

Consisting of the trial's lead investigators, independent medical monitor, and key members from Kazia Therapeutics, the SRT has reviewed all preliminary (non-final) safety and pharmacokinetic (PK) data, and unanimously agreed that the maximal tolerated dose (MTD) has been reached at 500mg twice a day (BID). Under the condition that continuous monotherapy administration will be used in future clinical trials, 400mg BID was identified as the starting recommended phase 2 dose (RP2D).  

A total of 26 patients received EVT801 across six dosing cohorts ranging from 50mg daily to 500mg BID.  In general, EVT801 was tolerated across all doses with the majority of toxicities being mild to moderate and transient in nature.  Eleven different cancer types (ex. colon, renal cell, pancreatic) were enrolled in the study, with advanced ovarian cancer being the most prevalent (11 patients).  These 11 patients had an average age of 67 years (range: 56-76) and a median time from diagnosis of nine years. Forty-six percent (46%) of the ovarian cancer patients had stable disease or better for at least three cycles of EVT801 therapy.    

EVT801 is a highly selective small molecule VEGFR3 tyrosine kinase inhibitor targeting tumour angiogenesis. Unlike traditional angiokinase inhibitors, we believe based on preclinical data that EVT801 has favorable immune activity (reduces immunosuppressive cells and no impact on CD3+ T-cells proliferation) and stabilizes tumor blood vessels, minimizing hypoxia and therefore decreases the potential for metastatic spread. The Phase 1 EVT801 monotherapy dose-finding trial targets patients with histologically confirmed advanced or metastatic solid tumours that are unresponsive to standard treatment, or for whom no standard treatment is available or appropriate.

Kazia Therapeutics CEO, Dr. John Friend said: "We are extremely pleased that the primary and secondary end points of stage 1 of the Phase 1 clinical trial have been met. The signals of clinical activity, especially in patients with advanced ovarian cancer are highly encouraging as we continue to progress the clinical development program for EVT801 as a potential first-in-class VEGFR3 inhibitor. With a median survival time of less than 4 years, there is a large unmet need for new therapies in patients with high-grade serous ovarian cancer."

The Phase 1, open label study is designed to assess the safety, tolerability, and PK of EVT801 in patients with advanced or metastatic solid tumors unresponsive to standard treatment, or for whom no standard treatment is available or appropriate.

Primary Objective:

  • To evaluate the safety and tolerability of EVT801 in subjects with
    advanced or metastatic solid tumours.
  • To determine the MTD and / or a RP2D of EVT801 when
    administered daily to subjects with advanced or metastatic solid

Secondary Objectives:

  • To characterise the PK of EVT801 following administration in an oral
    capsule formulation.
  • To identify active metabolites of EVT801 in plasma.
  • To determine preliminary anti–tumour activity of EVT801 via
    assessment of overall response rate.


We look forward to sharing the final stage 1 data and next development steps at an upcoming scientific conference in the second half of 2024. 

About Kazia Therapeutics Limited

Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia.

Our lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed Phase 2 study in glioblastoma reported early signals of clinical activity in 2021, and a pivotal study in glioblastoma, GBM AGILE, is ongoing, with final data expected in 1H2024. Other clinical trials are ongoing in brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these having reported encouraging interim data.

Paxalisib was granted Orphan Drug Designation for glioblastoma by the FDA in February 2018, and FTD for glioblastoma by the FDA in August 2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid tumour brain metastases harboring PI3K pathway mutations in combination with radiation therapy. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020, and for atypical teratoid / rhabdoid tumours in June 2022 and July 2022, respectively.

Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided evidence of synergy with immuno-oncology agents. Stage one of the Phase I study has been completed and preliminary data is anticipated in CY2024.

For more information, please visit or follow us on Twitter @KaziaTx.

Forward-Looking Statements

This announcement may contain forward-looking statements, which can generally be identified as such by the use of words such as "may," "will," "estimate," "future," "forward," "anticipate," or other similar words. Any statement describing Kazia's future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements regarding: the timing for results and data related to Kazia's clinical and preclinical trials, Kazia's strategy and plans with respect to its programs, including paxalisib and EVT801, the potential benefits of EVT801 as a VEGFR3  inhibitor and the potential market opportunity for EVT801. Such statements are based on Kazia's current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties: associated with clinical and preclinical trials and product development, related to regulatory approvals, and related to the impact of global economic conditions. These and other risks and uncertainties are described more fully in Kazia's Annual Report, filed on form 20-F with the SEC, and in subsequent filings with the United States Securities and Exchange Commission. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement.

This announcement was authorized for release by Dr John Friend, CEO.

Cision View original content to download multimedia:

SOURCE Kazia Therapeutics Limited

Kazia Therapeutics Limited


KZIA Rankings

KZIA Latest News

KZIA Stock Data

Pharmaceutical Preparation Manufacturing
United States of America